fbpx

ADVERTISEMENT

ADVERTISEMENT

Bipolar Disorder

Updated : September 7, 2023





Background

  • Bipolar disorder, or manic-depressive illness, is a mental health condition characterized by extreme mood swings that include periods of elevated or irritable mood (mania or hypomania) and depressive episodes. These mood episodes can last for days, weeks, or even months, significantly impacting a person’s ability to function and maintain stable relationships.

Epidemiology

  • The estimated lifetime prevalence of bipolar I disorder, according to the National Institute of Mental Health in the United States, is approximately 2.6%. The prevalence of bipolar II disorder is estimated to be around 0.5%-1%.
  • The onset of bipolar disorder occurs in late adolescence or early adulthood, with an average age of onset being around 25 years.
    Bipolar disorder often coincides with other mental health conditions. Common comorbidities include anxiety disorders, substance use disorders, attention-deficit/hyperactivity disorder (ADHD), and eating disorders.
  • Bipolar disorder affects both males and females, but there are some gender differences in the presentation of the illness. Bipolar I disorder affects males and females equally, while bipolar II disorder may be slightly more common in females.

Anatomy

Pathophysiology

  • Imbalanced neurotransmitters, chemical messengers in the brain, are thought to play a significant role in bipolar disorder. Specifically, abnormalities in serotonin, norepinephrine, and dopamine levels or functioning have been observed. These imbalances can disrupt mood regulation, leading to the characteristic mood swings reported in bipolar disorder.
  • Neuroimaging studies portray structural and functional differences in the brains of individuals with bipolar disorder. These differences involve regions responsible for emotional regulation, like the amygdala, prefrontal cortex, and hippocampus. Changes in these brain areas may affect mood stability and emotional processing.

Etiology

The etiology of bipolar disorder involves a combination of genetic, biological, environmental, and psychosocial factors. While the exact cause is not fully understood, research suggests the following factors contribute to the development of bipolar disorder:
Genetic Factors: Bipolar disorder has a significant genetic component. Family and twin studies have demonstrated a higher risk of the disorder in individuals with close relatives who have bipolar disorder. Specific genes and genetic variations are being studied better to understand their role in the disorder’s etiology.
Neurobiological Factors: Imbalances in neurotransmitters, such as serotonin, norepinephrine, and dopamine, are thought to contribute to the etiology of bipolar disorder. Abnormalities in the functioning and regulation of these neurotransmitters can disrupt mood regulation and lead to the characteristic mood swings seen in the disorder.
Environmental Factors: Stressful events, such as trauma, loss, or significant life changes, may trigger mood episodes. Substance abuse, including alcohol and drug use, can also contribute to developing and exacerbating bipolar disorder. Additionally, disruptions in sleep patterns, social support, and interpersonal relationships may impact the course of the disorder.
Psychosocial Factors: Psychosocial factors, such as childhood adversity, early life trauma, and dysfunctional family dynamics, increase the risk of developing bipolar disorder. These factors can contribute to the vulnerability and expression of the disorder through their impact on stress response systems, coping mechanisms, and emotional regulation.

Genetics

Prognostic Factors

Clinical History

Non-specific signs & symptoms:
• Mood swings
• Hypomania
• Depression
• Mania
• Irritability
• Impulsiveness
• Loss of interest
• Changes in appetite
• Cognitive impairment
Systemic signs & symptoms
• Fatigue
• Weight disturbances

Physical Examination

When evaluating a patient with suspected bipolar disorder, a comprehensive physical examination is typically conducted to rule out any underlying medical conditions that may contribute to the symptoms or affect treatment decisions. While bipolar disorder primarily involves mood and behavioral symptoms, a physical examination helps assess the patient’s overall health and identify any physical signs that may be relevant. Here are some components of a physical examination that may be performed:
Vital Signs: Measure blood pressure, heart rate, respiratory rate, and body temperature to assess the patient’s basic physiological parameters.
General Appearance: Observing the patient’s overall appearance, including their level of distress, hygiene, grooming, and any significant physical abnormalities.
Neurological Examination: Assessing the patient’s neurological function, including coordination, muscle strength, reflexes, sensation, and cranial nerve examination.
Cardiovascular Examination: Evaluating the heart and blood vessels, including auscultating the heart sounds, checking for any murmurs or abnormalities, and assessing peripheral pulses.
Respiratory Examination: Assessing the lungs and respiratory system, including auscultating breath sounds and evaluating the respiratory effort.
Abdominal Examination: Palpating the abdomen for tenderness, masses, or organ enlargement. Checking for liver or spleen enlargement.
Skin Examination: Inspect the skin for rashes, lesions, or other dermatological findings relevant to the patient’s health.
Weight and Body Mass Index (BMI): Measuring the patient’s weight and calculating their BMI to assess any significant weight changes or abnormalities.

Age group

• Children • Adults • Older Adults

Associated comorbidity

• Substance abuse
• Anxiety disorders
• Attention deficit hyperactivity disorder
• Eating disorders
• Sleep disturbances
• Cardiovascular disease
• Diabetes

Associated activity

Acuity of presentation

  • The acuity of presentation in bipolar disorder refers to the severity and intensity of symptoms at the time of diagnosis or assessment. It can vary depending on the phase of the illness and the specific episode experienced. The different levels of acuity commonly observed in the presentation of bipolar disorder are acute manic episodes, acute depressive episodes, mixed episodes, and chronic mood instability.

Differential Diagnoses

• Major depressive disorder
• Schizophrenia
• Anxiety disorders
• Substance use disorder
• Borderline personality disorder
• Attention deficit hyperactivity disorder in pediatrics

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

  • The treatment of bipolar disorder typically involves a combination of medication, psychotherapy, and lifestyle modifications.
  • Electroconvulsive therapy: Electroconvulsive therapy (ECT) is a medical procedure that involves inducing controlled seizures in a person’s brain using electrical currents. It is sometimes used as a treatment option for bipolar disorder, particularly when other treatments have been ineffective or when rapid and significant improvement is necessary.

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Atypical antipsychotic medications, such as aripiprazole, quetiapine, olanzapine, and risperidone, are commonly prescribed in bipolar disorder treatment. They can help manage acute manic or mixed episodes, reduce agitation, stabilize mood, and prevent future episodes. Atypical antipsychotics can be used as monotherapy or in combination with mood stabilizers.

  • Aripiprazole:
    aripiprazole modulates the activity of neurotransmitters in the brain, including dopamine and serotonin. It acts as a partial agonist at dopamine D2 receptors and a partial agonist at serotonin 5-HT1A receptors. This unique pharmacological profile is believed to contribute to its mood-stabilizing effects.
  • Quetiapine:
    quetiapine is primarily used to stabilize mood and help prevent episodes of mania or depression in individuals with bipolar disorder. It can effectively reduce the intensity and frequency of manic and depressive episodes.
    quetiapine is also approved for treating bipolar depression, which refers to the depressive phase of bipolar disorder. It can help alleviate symptoms such as sadness, loss of interest, sleep disturbances, and changes in appetite.
  • Olanzapine:
    olanzapine is primarily used as a mood stabilizer in treating bipolar disorder. It helps to regulate and stabilize mood, reducing the severity and frequency of manic and depressive episodes.
    olanzapine is particularly effective in treating the manic phase of bipolar disorder. It can help alleviate symptoms such as elevated mood, irritability, racing thoughts, and increased energy level.
  • Risperidone:
    risperidone is particularly effective in treating the manic phase of bipolar disorder. It can help alleviate agitation, irritability, impulsivity, and psychosis.
    risperidone may also be used for long-term maintenance treatment to prevent the recurrence of manic or depressive episodes in individuals with bipolar disorder. It can help maintain stability and reduce the risk of relapses.
  • Antidepressants: While the use of antidepressants in bipolar disorder is somewhat controversial due to the risk of triggering manic episodes or rapid cycling, they may be cautiously prescribed in some cases. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), may be used during depressive episodes in combination with mood stabilizers. Close monitoring is crucial to minimize the risk of inducing manic symptoms.
  • Benzodiazepines: Benzodiazepines, such as lorazepam or clonazepam, are sometimes prescribed for short-term use in managing acute anxiety, insomnia, or agitation associated with bipolar disorder. These medications have sedating properties and can help calm and stabilize mood during high anxiety or agitation episodes.
  • Anticonvulsants:     Besides traditional mood stabilizers like lithium and valproate, other anticonvulsant medications, such as carbamazepine and gabapentin, may be used to treat bipolar disorder. They can help stabilize mood, manage agitation, and reduce impulsivity.

The management of bipolar disorder typically involves several phases, including acute treatment, maintenance treatment, and long-term management. Here’s an overview of these phases:
• Acute treatment phase
• Maintenance phase
• Long-term management

Medication

 

asenapine

Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day



asenapine

Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day



risperidone 

Orally
Initial dose:2 to 3mg orally /day
Titration dose: Increase 1mg/day at 24 hours intervals
Maximum dose: 6mg orally /day

Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks



carbamazepine 

Indicated for bipolar mania:


Extended-release capsules:
Initial dose: 200mg orally twice a day
Increase every week by 200mg/dose divided every 6-8 hours
Maximum dose: 1600mg /day



quetiapine 

(Depressive Episodes)
The dosage can be titrated upward over four days using either extended-release or immediate-release tablets.
Day 1: 50 mg orally before bed.
Day 2: 100 mg orally before bed.
Day 3: 200 mg orally before bed.
Maintenance (from day 4): 300 mg orally before bed



Dose Adjustments

Mania, Bipolar I Disorder
Given either monotherapy or in the combination with lithium or divalproex.
Immediately release
on day 1: 100 mg orally divided every 12 hours
on day 2: 200 mg orally divided every 12 hours.
on day 3: 300 mg daily orally divided every 12 hours
on day 4: 400 mg daily orally divided every 12 hours
Additional dosage modifications, up to 800 mg daily by day 6, should be given in 200 mg/day increments.
Dosage: 400-800 mg daily, should not exceed more than 800 mg daily
. Extended release
On Day 1: 300 mg orally once a day
On Day 2: 600 mg orally once a day
Maintenance (after day 3): 400-800 mg daily orally
Maintenance, Bipolar I Disorder
Given in addition to divalproex or lithium
400-800 mg daily orally divided every 12 hours for immediate release
400-800 mg daily orally in a single dose, extended release
In general, patients in the maintenance phase continue to receive the same dose that was used to stabilise them.

ziprasidone 

Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.



Dose Adjustments

Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.

aripiprazole 

Orally
Initial dose of 15 mg/day orally; may be increased progressively; a maximum daily dose of 30 mg/day.
Adjunct to lithium or valproate:10 to 15 mg/day orally initially; 15 mg/day is the recommended daily dose; may be progressively increased; Do not exceed 30 mg/day.
Continue the stabilization dosage for up to 6 weeks; therapy beyond six weeks has not been investigated.

Abilify Maintena
Patients without prior exposure to aripiprazole should begin with a monthly 400 mg Intramuscular dose.
Only a healthcare expert should administer this medication through deep intramuscular injection into the deltoid or gluteal muscle.
Establish tolerance with aripiprazole orally before beginning Abilify Maintena medication; thoroughly evaluating tolerability may take up to 2 weeks.
In patients with known aripiprazole tolerance, continue aripiprazole orally (10 to 20 mg/day) or other oral antipsychotics for 14 days following the first injection.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month. Administer monthly dose no earlier than 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.

Abilify Asimtufii (intramuscular every two months)
Never consumed aripiprazole
Establish oral aripiprazole tolerability before initiating 960 mg Intramuscular every two months.
Up to two weeks may be required to assess tolerability in patients with known aripiprazole tolerance thoroughly; continue oral aripiprazole (10 to 20 mg/day) or other antipsychotics Orally for 14 days after the first injection.

Orally antipsychotic-treated
Administer the initial dose of oral aripiprazole along with 10 to 20 mg for 14 consecutive days. Known to tolerate aripiprazole and stable on another oral antipsychotic First injection along with oral antipsychotic medication for 14 consecutive days

Treatment with Abilify Maintena
Administration of Abilify Asimtufii 960 mg every two months instead of the next planned injection of Abilify Maintena (once monthly dose) is recommended for patients on Abilify Maintena. Administer the first injection of Abilify Asimtufii instead of the second or subsequent injection of Abilify Maintena.
If adverse reactions occur with Abilify Asimtufii 960 mg, the dosage may be reduced to 720 mg every two months.
May administer Abilify Asimtufii up to 2 weeks before or after the 2-month timepoint.



levomepromazine (methotrimeprazine) 

25 mg 3-4 times intramuscularly each day Initially, 50-75 mg orally each day divided into 2-3 doses
Increase the dose based on tolerability and response
Patients who take initial high doses should be on bed rest for a few days
A dose of more than 1gm/day may be required in psychotic patients



lithium 


Indicated for Bipolar Disorder
Extended-release: 900 mg-1800 mg every day orally divided two times a day
Immediate release: 900 mg-1800 mg every day orally divided 3-4 times a day
To reduce adverse drug reactions, decrease the initial dose
Until serum concentration and clinical conditions are balanced, serum lithium levels have to be monitored 12 hrs following the dose, two times a week and every other month afterward
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)



 

asenapine

Age: 10-17 years
2.5 sublingually every 12 hours a day; may increase to 5 mg sublingually every 12 hours a day after 3 days and to 10 mg sublingually every 12 hours a day after 3 additional days



risperidone 

<10 years: Safety and efficacy not established
>10 years:
Initial dose: 0.5mg/day orally in the morning or evening
Titration dose: may increase 0.5mg to 1mg/day at 24 hours intervals
Maximum dose: 6mg orally per day



aripiprazole 

10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day



aripiprazole 

10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day



lithium 


Indicated for Bipolar Disorder as off-label
Age >7 years, body weight <30 kg
300 mg orally two times a day, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age >7 years, body weight >30 kg
300 mg orally three times a day, the first week of treatment, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age <7 years
Safety and efficacy not established
Age >12 years
Extended-release tablets:
Body weight <22K.g: 600 mg in a day orally divided two times a day
Body weight 22-41K.g: 900 mg in a day orally divided two times a day
Body weight >41K.g: 1200 mg in a day orally divided two times a day
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Dose based on weight:
15 mg/kg/dose orally two times a day. It should not exceed 600 mg/dose as an initial dose
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal



 

risperidone 

Orally
Initially:0.5mg/day
At an interval of 24 hours, may increase the dose from 1-2mg/day
Maximum dose:16mg orally/day

Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks



quetiapine 

50-200 mg/day orally for immediate release; can increase to 25-50 mg daily
50 mg/day orally for extended release; may can be increased to 50 mg daily.



Dose Adjustments

Alzheimer's Disease-Related Psychosis and Agitation (Off-label)
12.5-50 mg daily orally at start; increased gradually as tolerated; should not exceed more than 200-300 mg daily

Media Gallary

References

• https://www.ncbi.nlm.nih.gov/books/NBK558998/
• https://www.ncbi.nlm.nih.gov/books/NBK547001/

ADVERTISEMENT 

Bipolar Disorder

Updated : September 7, 2023




  • Bipolar disorder, or manic-depressive illness, is a mental health condition characterized by extreme mood swings that include periods of elevated or irritable mood (mania or hypomania) and depressive episodes. These mood episodes can last for days, weeks, or even months, significantly impacting a person’s ability to function and maintain stable relationships.
  • The estimated lifetime prevalence of bipolar I disorder, according to the National Institute of Mental Health in the United States, is approximately 2.6%. The prevalence of bipolar II disorder is estimated to be around 0.5%-1%.
  • The onset of bipolar disorder occurs in late adolescence or early adulthood, with an average age of onset being around 25 years.
    Bipolar disorder often coincides with other mental health conditions. Common comorbidities include anxiety disorders, substance use disorders, attention-deficit/hyperactivity disorder (ADHD), and eating disorders.
  • Bipolar disorder affects both males and females, but there are some gender differences in the presentation of the illness. Bipolar I disorder affects males and females equally, while bipolar II disorder may be slightly more common in females.
  • Imbalanced neurotransmitters, chemical messengers in the brain, are thought to play a significant role in bipolar disorder. Specifically, abnormalities in serotonin, norepinephrine, and dopamine levels or functioning have been observed. These imbalances can disrupt mood regulation, leading to the characteristic mood swings reported in bipolar disorder.
  • Neuroimaging studies portray structural and functional differences in the brains of individuals with bipolar disorder. These differences involve regions responsible for emotional regulation, like the amygdala, prefrontal cortex, and hippocampus. Changes in these brain areas may affect mood stability and emotional processing.

The etiology of bipolar disorder involves a combination of genetic, biological, environmental, and psychosocial factors. While the exact cause is not fully understood, research suggests the following factors contribute to the development of bipolar disorder:
Genetic Factors: Bipolar disorder has a significant genetic component. Family and twin studies have demonstrated a higher risk of the disorder in individuals with close relatives who have bipolar disorder. Specific genes and genetic variations are being studied better to understand their role in the disorder’s etiology.
Neurobiological Factors: Imbalances in neurotransmitters, such as serotonin, norepinephrine, and dopamine, are thought to contribute to the etiology of bipolar disorder. Abnormalities in the functioning and regulation of these neurotransmitters can disrupt mood regulation and lead to the characteristic mood swings seen in the disorder.
Environmental Factors: Stressful events, such as trauma, loss, or significant life changes, may trigger mood episodes. Substance abuse, including alcohol and drug use, can also contribute to developing and exacerbating bipolar disorder. Additionally, disruptions in sleep patterns, social support, and interpersonal relationships may impact the course of the disorder.
Psychosocial Factors: Psychosocial factors, such as childhood adversity, early life trauma, and dysfunctional family dynamics, increase the risk of developing bipolar disorder. These factors can contribute to the vulnerability and expression of the disorder through their impact on stress response systems, coping mechanisms, and emotional regulation.

Non-specific signs & symptoms:
• Mood swings
• Hypomania
• Depression
• Mania
• Irritability
• Impulsiveness
• Loss of interest
• Changes in appetite
• Cognitive impairment
Systemic signs & symptoms
• Fatigue
• Weight disturbances

When evaluating a patient with suspected bipolar disorder, a comprehensive physical examination is typically conducted to rule out any underlying medical conditions that may contribute to the symptoms or affect treatment decisions. While bipolar disorder primarily involves mood and behavioral symptoms, a physical examination helps assess the patient’s overall health and identify any physical signs that may be relevant. Here are some components of a physical examination that may be performed:
Vital Signs: Measure blood pressure, heart rate, respiratory rate, and body temperature to assess the patient’s basic physiological parameters.
General Appearance: Observing the patient’s overall appearance, including their level of distress, hygiene, grooming, and any significant physical abnormalities.
Neurological Examination: Assessing the patient’s neurological function, including coordination, muscle strength, reflexes, sensation, and cranial nerve examination.
Cardiovascular Examination: Evaluating the heart and blood vessels, including auscultating the heart sounds, checking for any murmurs or abnormalities, and assessing peripheral pulses.
Respiratory Examination: Assessing the lungs and respiratory system, including auscultating breath sounds and evaluating the respiratory effort.
Abdominal Examination: Palpating the abdomen for tenderness, masses, or organ enlargement. Checking for liver or spleen enlargement.
Skin Examination: Inspect the skin for rashes, lesions, or other dermatological findings relevant to the patient’s health.
Weight and Body Mass Index (BMI): Measuring the patient’s weight and calculating their BMI to assess any significant weight changes or abnormalities.

• Children • Adults • Older Adults

• Substance abuse
• Anxiety disorders
• Attention deficit hyperactivity disorder
• Eating disorders
• Sleep disturbances
• Cardiovascular disease
• Diabetes

  • The acuity of presentation in bipolar disorder refers to the severity and intensity of symptoms at the time of diagnosis or assessment. It can vary depending on the phase of the illness and the specific episode experienced. The different levels of acuity commonly observed in the presentation of bipolar disorder are acute manic episodes, acute depressive episodes, mixed episodes, and chronic mood instability.

• Major depressive disorder
• Schizophrenia
• Anxiety disorders
• Substance use disorder
• Borderline personality disorder
• Attention deficit hyperactivity disorder in pediatrics

  • The treatment of bipolar disorder typically involves a combination of medication, psychotherapy, and lifestyle modifications.
  • Electroconvulsive therapy: Electroconvulsive therapy (ECT) is a medical procedure that involves inducing controlled seizures in a person’s brain using electrical currents. It is sometimes used as a treatment option for bipolar disorder, particularly when other treatments have been ineffective or when rapid and significant improvement is necessary.

  • Aripiprazole:
    aripiprazole modulates the activity of neurotransmitters in the brain, including dopamine and serotonin. It acts as a partial agonist at dopamine D2 receptors and a partial agonist at serotonin 5-HT1A receptors. This unique pharmacological profile is believed to contribute to its mood-stabilizing effects.
  • Quetiapine:
    quetiapine is primarily used to stabilize mood and help prevent episodes of mania or depression in individuals with bipolar disorder. It can effectively reduce the intensity and frequency of manic and depressive episodes.
    quetiapine is also approved for treating bipolar depression, which refers to the depressive phase of bipolar disorder. It can help alleviate symptoms such as sadness, loss of interest, sleep disturbances, and changes in appetite.
  • Olanzapine:
    olanzapine is primarily used as a mood stabilizer in treating bipolar disorder. It helps to regulate and stabilize mood, reducing the severity and frequency of manic and depressive episodes.
    olanzapine is particularly effective in treating the manic phase of bipolar disorder. It can help alleviate symptoms such as elevated mood, irritability, racing thoughts, and increased energy level.
  • Risperidone:
    risperidone is particularly effective in treating the manic phase of bipolar disorder. It can help alleviate agitation, irritability, impulsivity, and psychosis.
    risperidone may also be used for long-term maintenance treatment to prevent the recurrence of manic or depressive episodes in individuals with bipolar disorder. It can help maintain stability and reduce the risk of relapses.
  • Antidepressants: While the use of antidepressants in bipolar disorder is somewhat controversial due to the risk of triggering manic episodes or rapid cycling, they may be cautiously prescribed in some cases. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), may be used during depressive episodes in combination with mood stabilizers. Close monitoring is crucial to minimize the risk of inducing manic symptoms.
  • Benzodiazepines: Benzodiazepines, such as lorazepam or clonazepam, are sometimes prescribed for short-term use in managing acute anxiety, insomnia, or agitation associated with bipolar disorder. These medications have sedating properties and can help calm and stabilize mood during high anxiety or agitation episodes.
  • Anticonvulsants:     Besides traditional mood stabilizers like lithium and valproate, other anticonvulsant medications, such as carbamazepine and gabapentin, may be used to treat bipolar disorder. They can help stabilize mood, manage agitation, and reduce impulsivity.

The management of bipolar disorder typically involves several phases, including acute treatment, maintenance treatment, and long-term management. Here’s an overview of these phases:
• Acute treatment phase
• Maintenance phase
• Long-term management

asenapine

Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day



asenapine

Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day



risperidone 

Orally
Initial dose:2 to 3mg orally /day
Titration dose: Increase 1mg/day at 24 hours intervals
Maximum dose: 6mg orally /day

Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks



carbamazepine 

Indicated for bipolar mania:


Extended-release capsules:
Initial dose: 200mg orally twice a day
Increase every week by 200mg/dose divided every 6-8 hours
Maximum dose: 1600mg /day



quetiapine 

(Depressive Episodes)
The dosage can be titrated upward over four days using either extended-release or immediate-release tablets.
Day 1: 50 mg orally before bed.
Day 2: 100 mg orally before bed.
Day 3: 200 mg orally before bed.
Maintenance (from day 4): 300 mg orally before bed



Dose Adjustments

Mania, Bipolar I Disorder
Given either monotherapy or in the combination with lithium or divalproex.
Immediately release
on day 1: 100 mg orally divided every 12 hours
on day 2: 200 mg orally divided every 12 hours.
on day 3: 300 mg daily orally divided every 12 hours
on day 4: 400 mg daily orally divided every 12 hours
Additional dosage modifications, up to 800 mg daily by day 6, should be given in 200 mg/day increments.
Dosage: 400-800 mg daily, should not exceed more than 800 mg daily
. Extended release
On Day 1: 300 mg orally once a day
On Day 2: 600 mg orally once a day
Maintenance (after day 3): 400-800 mg daily orally
Maintenance, Bipolar I Disorder
Given in addition to divalproex or lithium
400-800 mg daily orally divided every 12 hours for immediate release
400-800 mg daily orally in a single dose, extended release
In general, patients in the maintenance phase continue to receive the same dose that was used to stabilise them.

ziprasidone 

Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.



Dose Adjustments

Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.

aripiprazole 

Orally
Initial dose of 15 mg/day orally; may be increased progressively; a maximum daily dose of 30 mg/day.
Adjunct to lithium or valproate:10 to 15 mg/day orally initially; 15 mg/day is the recommended daily dose; may be progressively increased; Do not exceed 30 mg/day.
Continue the stabilization dosage for up to 6 weeks; therapy beyond six weeks has not been investigated.

Abilify Maintena
Patients without prior exposure to aripiprazole should begin with a monthly 400 mg Intramuscular dose.
Only a healthcare expert should administer this medication through deep intramuscular injection into the deltoid or gluteal muscle.
Establish tolerance with aripiprazole orally before beginning Abilify Maintena medication; thoroughly evaluating tolerability may take up to 2 weeks.
In patients with known aripiprazole tolerance, continue aripiprazole orally (10 to 20 mg/day) or other oral antipsychotics for 14 days following the first injection.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month. Administer monthly dose no earlier than 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.

Abilify Asimtufii (intramuscular every two months)
Never consumed aripiprazole
Establish oral aripiprazole tolerability before initiating 960 mg Intramuscular every two months.
Up to two weeks may be required to assess tolerability in patients with known aripiprazole tolerance thoroughly; continue oral aripiprazole (10 to 20 mg/day) or other antipsychotics Orally for 14 days after the first injection.

Orally antipsychotic-treated
Administer the initial dose of oral aripiprazole along with 10 to 20 mg for 14 consecutive days. Known to tolerate aripiprazole and stable on another oral antipsychotic First injection along with oral antipsychotic medication for 14 consecutive days

Treatment with Abilify Maintena
Administration of Abilify Asimtufii 960 mg every two months instead of the next planned injection of Abilify Maintena (once monthly dose) is recommended for patients on Abilify Maintena. Administer the first injection of Abilify Asimtufii instead of the second or subsequent injection of Abilify Maintena.
If adverse reactions occur with Abilify Asimtufii 960 mg, the dosage may be reduced to 720 mg every two months.
May administer Abilify Asimtufii up to 2 weeks before or after the 2-month timepoint.



levomepromazine (methotrimeprazine) 

25 mg 3-4 times intramuscularly each day Initially, 50-75 mg orally each day divided into 2-3 doses
Increase the dose based on tolerability and response
Patients who take initial high doses should be on bed rest for a few days
A dose of more than 1gm/day may be required in psychotic patients



lithium 


Indicated for Bipolar Disorder
Extended-release: 900 mg-1800 mg every day orally divided two times a day
Immediate release: 900 mg-1800 mg every day orally divided 3-4 times a day
To reduce adverse drug reactions, decrease the initial dose
Until serum concentration and clinical conditions are balanced, serum lithium levels have to be monitored 12 hrs following the dose, two times a week and every other month afterward
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)



asenapine

Age: 10-17 years
2.5 sublingually every 12 hours a day; may increase to 5 mg sublingually every 12 hours a day after 3 days and to 10 mg sublingually every 12 hours a day after 3 additional days



risperidone 

<10 years: Safety and efficacy not established
>10 years:
Initial dose: 0.5mg/day orally in the morning or evening
Titration dose: may increase 0.5mg to 1mg/day at 24 hours intervals
Maximum dose: 6mg orally per day



aripiprazole 

10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day



aripiprazole 

10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day



lithium 


Indicated for Bipolar Disorder as off-label
Age >7 years, body weight <30 kg
300 mg orally two times a day, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age >7 years, body weight >30 kg
300 mg orally three times a day, the first week of treatment, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age <7 years
Safety and efficacy not established
Age >12 years
Extended-release tablets:
Body weight <22K.g: 600 mg in a day orally divided two times a day
Body weight 22-41K.g: 900 mg in a day orally divided two times a day
Body weight >41K.g: 1200 mg in a day orally divided two times a day
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Dose based on weight:
15 mg/kg/dose orally two times a day. It should not exceed 600 mg/dose as an initial dose
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal



risperidone 

Orally
Initially:0.5mg/day
At an interval of 24 hours, may increase the dose from 1-2mg/day
Maximum dose:16mg orally/day

Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks



quetiapine 

50-200 mg/day orally for immediate release; can increase to 25-50 mg daily
50 mg/day orally for extended release; may can be increased to 50 mg daily.



Dose Adjustments

Alzheimer's Disease-Related Psychosis and Agitation (Off-label)
12.5-50 mg daily orally at start; increased gradually as tolerated; should not exceed more than 200-300 mg daily

• https://www.ncbi.nlm.nih.gov/books/NBK558998/
• https://www.ncbi.nlm.nih.gov/books/NBK547001/